Filing Details
- Accession Number:
- 0001062993-24-010536
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-16 19:20:35
- Reporting Period:
- 2024-05-14
- Accepted Time:
- 2024-05-16 19:20:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1267565 | Collegium Pharmaceutical Inc | COLL | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1254705 | G Garen Bohlin | C/O Collegium Pharmaceutical, Inc. 100 Technology Center Drive Stoughton MA 02072 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-05-14 | 28,985 | $5.73 | 73,760 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-05-14 | 28,985 | $32.30 | 44,775 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2024-05-16 | 7,693 | $0.00 | 52,468 | No | 4 | A | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Purchase) | Disposition | 2024-05-14 | 28,985 | $0.00 | 28,985 | $5.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-03-19 | No | 4 | M | Direct |
Footnotes
- The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
- The option is fully vested and exercisable.
Billionaire Hedge Funds
